<DOC>
	<DOCNO>NCT01196481</DOCNO>
	<brief_summary>Patients cirrhosis enrol large esophageal varix , never bleed . After successful screen baseline hepatic venous pressure gradient ( HVPG ) measure . Tablet carvedilol 3.125 mg BD 1 week start . It increase 6.25 mg BD continue next 7 week . After completion 8 week hepatic venous pressure gradient ( HVPG ) measure find responder ( hepatic venous pressure gradient â‰¥20 % reduction baseline absolute value hepatic venous pressure gradient &lt; 12 mm Hg ) non responder ( hepatic venous pressure gradient &lt; 20 % reduction ) .The responder exclude study non responder randomize carvedilol+VSL # 3 versus Endoscopic Variceal Ligation .</brief_summary>
	<brief_title>Carvedilol + VSL # 3 Versus Endoscopic Variceal Ligation Primary Prophylaxis Esophageal Variceal Bleeding Cirrhotic Patients Non Responder Carvedilol .</brief_title>
	<detailed_description />
	<mesh_term>Carvedilol</mesh_term>
	<criteria>Patients cirrhosis portal hypertension age 18 75 year large esophageal varix without red color sign bleed previously . Any contraindication betablockers Coagulopathy INR &gt; 1.8 time enrollment Any Endoscopic Variceal Ligation sclerotherapy within last 3 month Any past history surgery portal hypertension Significant cardio pulmonary comorbidity Any malignancy Refusal participate study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>December 2015</verification_date>
</DOC>